Brentuximab Vedotin (SGN-35) in Patients With Relapsed or Refractory Systemic Anaplastic Large-Cell Lymphoma: Results of a Phase II Study
Open accessThe DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Abstract
Purpose: Systemic anaplastic large-cell lymphoma (ALCL) is an aggressive subtype of T-cell lymphoma characterized by the uniform expression of CD30. The antibody-drug conjugate brentuximab vedotin delivers the potent antimicrotubule agent monomethylauristatin E to CD30-positive malignant cells. A phase II multicenter trial was conducted to evaluate the efficacy and safety of brentuximab vedotin in patients with relapsed or refractory systemic ALCL. Patients and Methods: Patients with systemic ALCL and recurrent disease after at least one prior therapy received brentuximab vedotin 1.8 mg/kg intravenously every 3 weeks over 30 minutes as an outpatient infusion. The primary end point of the study was overall objective response rate as assessed by independent central review. Results: Of 58 patients treated in the study, 50 patients (86%) achieved an objective response, 33 patients (57%) achieved a complete remission (CR), and 17 patients (29%) achieved a partial remission. The median durations of overall response and CR were 12.6 and 13.2 months, respectively. Grade 3 or 4 adverse events in ≥ 10% of patients were neutropenia (21%), thrombocytopenia (14%), and peripheral sensory neuropathy (12%). Conclusion: Brentuximab vedotin induced objective responses in the majority of patients and CRs in more than half of patients with recurrent systemic ALCL. Targeted therapy with this CD30-directed antibody-drug conjugate may be an effective treatment for relapsed or refractory systemic ALCL and warrants further studies in front-line therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Toxicity and response criteria of the Eastern Cooperative Oncology Group
Oken, M. M., Creech, R. H., Tormey, D. C., Horton, J., Davis, T. E., McFadden, E. T., & Carbone, P. P. (1982) · AMERICAN JOURNAL OF CLINICAL ONCOLOGY · doi:10.1097/00000421-198212000-00014 · Cited by 11,647
Revised Response Criteria for Malignant Lymphoma
Cheson, B. D., Pfistner, B., Juweid, M. E., Gascoyne, R. D., Specht, L., Horning, S. J., Coiffier, B., Fisher, R. I., Hagenbeek, A., Zucca, E., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.2403 · Cited by 4,426
Self-citationWHO Classification: Tumours of the Haematopoietic and Lymphoid Tissues (2008)
(2015) · Postgraduate Haematology · doi:10.1002/9781118853771.ch51 · Cited by 3,290
The Robust Inference for the Cox Proportional Hazards Model
Lin, D. Y., & Wei, L. J. (1989) · Journal of the American Statistical Association · doi:10.1080/01621459.1989.10478874 · Cited by 2,695
Coiffier, B., Thieblemont, C., Van Den Neste, E., Lepeu, G., Plantier, I., Castaigne, S., Lefort, S., Marit, G., Macro, M., Sebban, C., et al. (2010) · Blood · doi:10.1182/blood-2010-03-276246 · Cited by 1,540
Brentuximab Vedotin (SGN-35) for Relapsed CD30-Positive Lymphomas
Younes, A., Bartlett, N. L., Leonard, J. P., Kennedy, D. A., Lynch, C. M., Sievers, E. L., & Forero-Torres, A. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1002965 · Cited by 1,368
Self-citationFrancisco, J. A., Cerveny, C. G., Meyer, D. L., Mixan, B. J., Klussman, K., Chace, D. F., Rejniak, S. X., Gordon, K. A., DeBlanc, R., Toki, B. E., et al. (2003) · Blood · doi:10.1182/blood-2003-01-0039 · Cited by 931
Savage, K. J., Harris, N. L., Vose, J. M., Ullrich, F., Jaffe, E. S., Connors, J. M., Rimsza, L., Pileri, S. A., Chhanabhai, M., Gascoyne, R. D., et al. (2008) · Blood · doi:10.1182/blood-2008-01-134270 · Cited by 863
Self-citationO'Connor, O. A., Pro, B., Pinter-Brown, L., Bartlett, N., Popplewell, L., Coiffier, B., Jo Lechowicz, M., Savage, K. J., Shustov, A. R., Gisselbrecht, C., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.29.9024 · Cited by 647
Self-citationPeripheral Neuropathy Induced by Microtubule-Stabilizing Agents
Lee, J. J., & Swain, S. M. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.0543 · Cited by 472
Cited by
Antibody drug conjugate: the “biological missile” for targeted cancer therapy
Fu, Z., Li, S., Han, S., Shi, C., & Zhang, Y. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00947-7 · Cited by 1,643
Armitage, J. O., Gascoyne, R. D., Lunning, M. A., & Cavalli, F. (2017) · The Lancet · doi:10.1016/s0140-6736(16)32407-2 · Cited by 1,176
Antibody–drug conjugates for cancer
Chau, C. H., Steeg, P. S., & Figg, W. D. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31774-x · Cited by 816
Antibody–Drug Conjugates: A Comprehensive Review
Khongorzul, P., Ling, C. J., Khan, F. U., Ihsan, A. U., & Zhang, J. (2020) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-19-0582 · Cited by 787
Antibody-Drug Conjugates in Cancer Therapy
Sievers, E. L., & Senter, P. D. (2013) · Annual Review of Medicine · doi:10.1146/annurev-med-050311-201823 · Cited by 770
Self-citationSenter, P. D., & Sievers, E. L. (2012) · Nature Biotechnology · doi:10.1038/nbt.2289 · Cited by 763
Self-citationAntibody–drug conjugates for cancer therapy
Thomas, A., Teicher, B. A., & Hassan, R. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30030-4 · Cited by 606
Prince, H. M., Kim, Y. H., Horwitz, S. M., Dummer, R., Scarisbrick, J., Quaglino, P., Zinzani, P. L., Wolter, P., Sanches, J. A., Ortiz-Romero, P. L., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31266-7 · Cited by 588
Self-citationO'Connor, O. A., Horwitz, S., Masszi, T., Van Hoof, A., Brown, P., Doorduijn, J., Hess, G., Jurczak, W., Knoblauch, P., Chawla, S., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.59.2782 · Cited by 555
Self-citationDeclining childhood and adolescent cancer mortality
Smith, M. A., Altekruse, S. F., Adamson, P. C., Reaman, G. H., & Seibel, N. L. (2014) · Cancer · doi:10.1002/cncr.28748 · Cited by 542
“For anaplastic large cell lymphoma, both crizotinib and brentuximab vedotin have produced objective response rates in relapsed=refractory patients well above 50%.(19,20)”
BackgroundAntibody drug conjugates and bystander killing: is antigen-dependent internalisation required?
Staudacher, A. H., & Brown, M. P. (2017) · British Journal of Cancer · doi:10.1038/bjc.2017.367 · Cited by 540
Antibody-drug conjugates—an emerging class of cancer treatment
Diamantis, N., & Banerji, U. (2016) · British Journal of Cancer · doi:10.1038/bjc.2015.435 · Cited by 525
Cheson, B. D., Ansell, S., Schwartz, L., Gordon, L. I., Advani, R., Jacene, H. A., Hoos, A., Barrington, S. F., & Armand, P. (2016) · Blood · doi:10.1182/blood-2016-05-718528 · Cited by 521
Self-citationChimeric antigen receptor T-cell therapies for lymphoma
Brudno, J. N., & Kochenderfer, J. N. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.128 · Cited by 516
Emerging new therapeutic antibody derivatives for cancer treatment
Jin, S., Sun, Y., Liang, X., Gu, X., Ning, J., Xu, Y., Chen, S., & Pan, L. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00868-x · Cited by 459
Antibody-Drug Conjugate-Based Therapeutics: State of the Science
Birrer, M. J., Moore, K. N., Betella, I., & Bates, R. C. (2019) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djz035 · Cited by 439
Mak, V., Hamm, J., Chhanabhai, M., Shenkier, T., Klasa, R., Sehn, L. H., Villa, D., Gascoyne, R. D., Connors, J. M., & Savage, K. J. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.44.7524 · Cited by 437
Self-citationMechanisms of ADC Toxicity and Strategies to Increase ADC Tolerability
Nguyen, T. D., Bordeau, B. M., & Balthasar, J. P. (2023) · Cancers · doi:10.3390/cancers15030713 · Cited by 441
Clemens, M. W., Medeiros, L. J., Butler, C. E., Hunt, K. K., Fanale, M. A., Horwitz, S., Weisenburger, D. D., Liu, J., Morgan, E. A., Kanagal-Shamanna, R., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.63.3412 · Cited by 422
Self-citationAntibody–Drug Conjugates for Cancer Therapy
Hafeez, U., Parakh, S., Gan, H. K., & Scott, A. M. (2020) · Molecules · doi:10.3390/molecules25204764 · Cited by 395
Ogura, M., Ishida, T., Hatake, K., Taniwaki, M., Ando, K., Tobinai, K., Fujimoto, K., Yamamoto, K., Miyamoto, T., Uike, N., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.52.0924 · Cited by 362
Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin
Horwitz, S. M., Advani, R. H., Bartlett, N. L., Jacobsen, E. D., Sharman, J. P., O’Connor, O. A., Siddiqi, T., Kennedy, D. A., & Oki, Y. (2014) · Blood · doi:10.1182/blood-2013-12-542142 · Cited by 352
Self-citationClemens, M. W., Jacobsen, E. D., & Horwitz, S. M. (2019) · Aesthetic Surgery Journal · doi:10.1093/asj/sjy331 · Cited by 336
Antibody–Drug Conjugates for Cancer Treatment
Lambert, J. M., & Berkenblit, A. (2018) · Annual Review of Medicine · doi:10.1146/annurev-med-061516-121357 · Cited by 314
Antibody–Drug Conjugates (ADCs) for Personalized Treatment of Solid Tumors: A Review
Lambert, J. M., & Morris, C. Q. (2017) · Advances in Therapy · doi:10.1007/s12325-017-0519-6 · Cited by 304
“Early phase clinical trials of the ‘‘naked’’ anti-CD30 antibody showed no responses in HL, and, in ALCL patients, only 2 of 41 (5”
BackgroundInfluentialJacobsen, E. D., Sharman, J. P., Oki, Y., Advani, R. H., Winter, J. N., Bello, C. M., Spitzer, G., Palanca-Wessels, M. C., Kennedy, D. A., Levine, P., et al. (2015) · Blood · doi:10.1182/blood-2014-09-598763 · Cited by 300
Self-citationDuvic, M., Tetzlaff, M. T., Gangar, P., Clos, A. L., Sui, D., & Talpur, R. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.60.3787 · Cited by 299
Willemze, R., Hodak, E., Zinzani, P. L., Specht, L., & Ladetto, M. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt242 · Cited by 296
Horwitz, S. M., Koch, R., Porcu, P., Oki, Y., Moskowitz, A., Perez, M., Myskowski, P., Officer, A., Jaffe, J. D., Morrow, S. N., et al. (2018) · Blood · doi:10.1182/blood-2017-08-802470 · Cited by 290
Minard-Colin, V., Brugières, L., Reiter, A., Cairo, M. S., Gross, T. G., Woessmann, W., Burkhardt, B., Sandlund, J. T., Williams, D., Pillon, M., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.59.5827 · Cited by 290
Bridging Disulfides for Stable and Defined Antibody Drug Conjugates
Badescu, G., Bryant, P., Bird, M., Henseleit, K., Swierkosz, J., Parekh, V., Tommasi, R., Pawlisz, E., Jurlewicz, K., Farys, M., et al. (2014) · Bioconjugate Chemistry · doi:10.1021/bc500148x · Cited by 290
An Insight into FDA Approved Antibody-Drug Conjugates for Cancer Therapy
Tong, J. T. W., Harris, P. W. R., Brimble, M. A., & Kavianinia, I. (2021) · Molecules · doi:10.3390/molecules26195847 · Cited by 287
Kim, Y. H., Tavallaee, M., Sundram, U., Salva, K. A., Wood, G. S., Li, S., Rozati, S., Nagpal, S., Krathen, M., Reddy, S., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.60.3969 · Cited by 282
Self-citationCrizotinib in Advanced, Chemoresistant Anaplastic Lymphoma Kinase–Positive Lymphoma Patients
Gambacorti Passerini, C., Farina, F., Stasia, A., Redaelli, S., Ceccon, M., Mologni, L., Messa, C., Guerra, L., Giudici, G., Sala, E., et al. (2014) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djt378 · Cited by 279
CAR T‐Cell‐Based gene therapy for cancers: new perspectives, challenges, and clinical developments
Jogalekar, M. P., Rajendran, R. L., Khan, F., Dmello, C., Gangadaran, P., & Ahn, B.-C. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.925985 · Cited by 214
Morschhauser, F., Fitoussi, O., Haioun, C., Thieblemont, C., Quach, H., Delarue, R., Glaisner, S., Gabarre, J., Bosly, A., Lister, J., et al. (2013) · European Journal of Cancer · doi:10.1016/j.ejca.2013.04.029 · Cited by 131
U3-1402, a Novel HER3-Targeting Antibody-Drug Conjugate, for the Treatment of Colorectal Cancer
Koganemaru, S., Kuboki, Y., Koga, Y., Kojima, T., Yamauchi, M., Maeda, N., Kagari, T., Hirotani, K., Yasunaga, M., Matsumura, Y., et al. (2019) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-19-0452 · Cited by 90
“Although ADC development has been driven by hematological cancers (28-30), a new approach with HER2-targeted ADCs, such as trastuzumab emtansine or trastuzumab deruxtecan, has led to breakthrough results in”
BackgroundHaematological malignancies: at the forefront of immunotherapeutic innovation
Bachireddy, P., Burkhardt, U. E., Rajasagi, M., & Wu, C. J. (2015) · Nature Reviews Cancer · doi:10.1038/nrc3907 · Cited by 85
Phillips, A. A., Fields, P. A., Hermine, O., Ramos, J. C., Beltran, B. E., Pereira, J., Wandroo, F., Feldman, T., Taylor, G. P., Sawas, A., et al. (2019) · Haematologica · doi:10.3324/haematol.2018.205096 · Cited by 70
“5 (24-80) >65 years 11 (23) 1 (4) <40 years 6 (13) 7 (29)”
Albany, C., Einhorn, L., Garbo, L., Boyd, T., Josephson, N., & Feldman, D. R. (2018) · The Oncologist · doi:10.1634/theoncologist.2017-0544 · Cited by 51
“An ORR of 86% was observed in patients with systemic ALCL, with over 50% of patients achieving a CR [25].”
Background
Metadata
- Authors
- Pro, B., Advani, R., Brice, P., Bartlett, N. L., Rosenblatt, J. D., Illidge, T., Matous, J., Ramchandren, R., Fanale, M., Connors, J. M., Yang, Y., Sievers, E. L., Kennedy, D. A., & Shustov, A.
- Venue
- Journal of Clinical Oncology
- Published
- 2012-06-20
- Volume
- 30
- Issue
- 18
- Pages
- 2190-2196
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2139891818
- Cited by
- 997
- References
- 16
- FWCI
- 68.17
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.